The Community shall purchase five million doses of each of the following strains of foot-and-mouth disease antigen: - A5 European, - A22 Middle East, - O1 Middle East, - O1 European, up to a maximum cost of ECU 4 065 million. 2.
The antigen mentioned in paragraph 1 shall be supplied by Rhône-Mérieux, Pirbright Laboratory, Ash Road, Surrey, United Kingdom.
Payment to Rhône-Mérieux shall be made in accordance with the terms of the contract provided for in paragraph 1.
Article 3 The antigen shall be divided between the four antigen banks as follows: (a) Bayer, Cologne and the Institute for Animal health, Pirbright: 2,5 million doses of each of O1 European strain and A5 in each bank; (b) LNPB, Lyon and 1ZP, Brescia: 2,5 million doses of each of O1 Middle East strain and A22 in each bank.
Article 4 This Decision is addressed to the Member States.
Done at Brussels, 5 November 1993.
For the Commission René STEICHEN Member of the Commission (1) OJ No L 224, 18. 8. 1990, p. 19. (2) OJ No L 203, 13. 8. 1993, p. 34. (3) OJ No L 368, 31. 12. 1991, p. 21. (4) OJ No L 94, 28. 4. 1970, p. 13.
